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This data article is associated with the manuscript “GPVI surface
expression and signalling pathway activation are increased in
platelets from obese patients: elucidating potential anti-
atherothrombotic targets in obesity” [1]. The study refers to a
combination of different approaches in order to identify platelet-
derived biomarkers in obesity. A total of 34 obese patients and
their lean-matched controls were included in the study. We car-
ried out a proteomic and functional (aggregation assays) analysis
to find alterations in platelet-derived signalling pathways. After
that, biochemical and mechanistic (flow cytometry assays)estigacion en Medicina Molecular y Enfermedades Cronicas (CIMUS), Uni-
celona s/n, 15782, Santiago de Compostela, Spain.
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(CIMUS), Universid
Data accessibility Data are presente
Value of the data
 A combination of proteomics, biochemical and
biomarkers and drug targets in obesity
 The dataset can be utilized for comparative an
 The present data illustrates how the combinat
atherothrombotic targets in platelet-related diapproaches were done in order to confirm a hyperactivation of the
GPVI-related signalling pathway.
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s Group. Center for Research in Molecular Medicine and Chronic Diseases
ade Santiago de Compostela
d within this article and related to an original research article (in press)
functional approaches was carried out in order to obtain platelet-derived
alysis in platelets between obese and lean individuals
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seases1. Data
We performed a combination of 2D-DIGE-based proteomics, biochemical and functional ap-
proaches in order to identify biomarkers related to the risk of suffering atherothrombosis in obese
patients without cardiovascular disease (Fig. 1). Regarding the proteomic analysis, 1895 protein spots
were detected per gel, 55 of which were differentially regulated between obese and lean groups (fold
change cut-off  1.2; p < 0.05). We could successfully identify 35 protein features by MS which cor-
responded to 33 different ORFs (Table 1). Among others, we confirmed an up-regulation of aIIb and
fibrinogen isoforms in platelets from obese patients. Besides, a complementary platelet aggregation
approach showed platelets from obese patients are hyper-reactive in response to collagen and
collagen-related peptide (CRP), revealing the collagen receptor Glycoprotein VI (GPVI) signalling as one
of the altered pathways. We also found the active form of Src (pTyr418) is up-regulated in platelets
from obese individuals, which links proteomics and aggregation data. Moreover, we show that CRP-
activated platelets present higher levels of tyrosine phosphorylated PLCg2 in obese patients, con-
firming alterations in GPVI signalling. In line with the above, flow cytometry studies show higher
surface expression levels of total GPVI and GPVI-dimer in obese platelets, both correlating with BMI.
2. Experimental design, materials and methods
A detailed description of the material and methods used is provided in the accompanying research
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Table 1
Platelet proteins differentially regulated in obese patients versus lean healthy controls.
Uniprot code Name Spot Fold change





ACTG_HUMAN Actin, cytoplasmic 2 2550 þ1.2
4461 þ1.2
ACTN1_HUMAN Alpha-actinin-1 4465 þ1.2
4405 þ1.3
4403 þ1.3
ALBU_HUMAN Serum albumin 4424 1.2
4356 þ1.3
ANXA5_HUMAN Annexin A5 4356 þ1.3
ARK72_HUMAN Aflatoxin B1 aldehyde reductase member 2 2898 1.2
DCTN2_HUMAN Dynactin subunit 2 4354 1.2
DPYL2_HUMAN Dihydropyrimidinase-related protein 2 1858 1.2
FIBB_HUMAN Fibrinogen beta chain 2547 þ1.2
2077 þ1.2





GELS_HUMAN Gelsolin 4508 1.2
4505 1.2
GPDM_HUMAN Glycerol-3-phosphate dehydrogenase, mitochondrial 4400 1.4
HEM2_HUMAN Delta-aminolevulinic acid dehydratase 2932 1.2
HSPB1_HUMAN Heat shock protein beta-1 4361 1.2
3287 1.2
ITA2B_HUMAN Integrin aIIb 993 þ1.2
1006 þ1.2
LYSC_HUMAN Lysozyme C 4320 1.3
ODO2_HUMAN Dihydrolipoyllysine-residue succinyltransferase component of 2-
oxoglutarate dehydrogenase complex, mitochondrial
2077 þ1.2
PDLI1_HUMAN PDZ and LIM domain protein 1 2782 1.2
PDIA6_HUMAN Protein disulfide-isomerase A6 4354 1.2
PGM2_HUMAN Phosphoglucomutase-2 1711 1.2
PI42A_HUMAN Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha 4359 1.2
PP1R7_HUMAN Protein phosphatase 1 regulatory subunit 7 4465 þ1.2
SEPT2_HUMAN Septin-2 2547 þ1.2
SEP11_HUMAN Septin-11 4359 1.2
STIP1_HUMAN Stress-induced-phosphoprotein 1 1858 1.2
TBB1_HUMAN Tubulin beta-1 chain 4354 1.2
TPM1_HUMAN Tropomyosin alpha-1 chain 4424 1.2
4348 1.2





TXNL1_HUMAN Thioredoxin-like protein 1 2867 þ1.2
TYPH_HUMAN Thymidine phosphorylase 2021 þ1.2
VINC_HUMAN Vinculin 933 þ1.2
1006 þ1.2
VP37B_HUMAN Vacuolar protein sorting-associated protein 37B 2932 1.2
ZYX_HUMAN Zyxin 4491 1.2
4339 1.3
a. A positive fold change indicates that the protein feature is up-regulated in obese patients, whereas a negative fold change
indicates that the spot is down-regulate.
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The study was approved by the local Ethics Committee (Galician Investigation Ethics Committee)
and developed according to the principles outlined in the Declaration of Helsinki. All methods were
carried out in accordance with the approved guidelines, and written informed consent was obtained
from all subjects. At the moment of diagnosis, the obese patients were asked to participate in the study.
In the case of acceptance, they signed the informed consent, and 36 mL of blood were collected in
sodium citrate Vacuette® tubes for analyses.
Thirty-four patients referred to the Endocrinology Unit at the Santiago de Compostela University
Hospital, Spain, participated in the study. These patients had a BMI higher than 40, indicating severe
“healthy” obesity, and were referred to hospital by the primary care physician so they could be treated
by an endocrinologist. Exclusion criteria were coagulation disorders, platelet-associated disorders,
chronic antiplatelet drugs and other chronic drug therapy (except for drugs required to treat pre-
existing clinical factors that do not affect platelet reactivity). The lean control group consisted of
healthy normal weight volunteers recruited at the Santiago de Compostela University Health Service.
This group was age- and gender-matched with the obese group and individuals had a BMI between 18
and 26.
Additionally, another group of 11 healthy volunteers with BMI between 26 and 35 (overweight and
grade 1 obese individuals) was included in the study in order to investigate the expression levels of
GPVI in the platelet surface. This group, age-matched with the other groups, was also recruited at the
Santiago de Compostela University Health Service.2.2. Platelet isolation
Fresh blood samples (36 mL) were collected from obese patients and lean matched-controls in
coagulation 3.2% sodium citrate Vacuette® tubes and processed in less than 60 min. In order to obtain
the platelet-rich plasma (PRP), blood was centrifuged for 20 min at 200 g at room temperature.
Washed platelets were isolated following an established method that limits blood cells or plasma
proteins contaminations [2]. Briefly, upon addition of warmed (30 C) acid citrate dextrose (ACD)
solution (117 mM sodium citrate, 111 mM glucose, 78 mM citric acid) to a concentration of 7% v/v, the
blood was centrifuged for 20 min at 200g at room temperature to obtain PRP. The upper two thirds of
the PRPwas centrifuged in a fresh tube at 1000g in the presence of prostacyclin (final concentration 0.2
mg/mL), which allowed pelleting of platelets. Following removal of plasma, platelets were washed in
Tyrodes-HEPES (134 mmol/L NaCl, 0.34 mmol/L Na2HPO4, 2.9 mmol/LKCl, 12 mmol/L NaHCO3, 20
mmol/L HEPES, 5 mmol/L glucose, 1 mmol/L MgCl2, pH 7.3). Final washed platelet pellets were
resuspended in HEPES-Tyrodes (134 mmol/L NaCl, 0.34 mmol/L Na2HPO4, 2.9 mmol/L KCl, 12 mmol/L
NaHCO3, 20 mmol/L HEPES, 5 mmol/L glucose, 1 mmol/L MgCl2, pH 7.3) and allowed to rest for 30
minutes at room temperature. For proteomic studies based on two-dimensional differential gel elec-
trophoresis (2D-DIGE), concentrations of 8  108 platelets/mL were lysed in a NP-40-based lysis buffer
(0.3 M Sodium Chloride, 20mM Tris, 2mM EGTA, 2mM EDTA, 2% (v/v) NP-40, pH 7.5) and stored at
80 C [3].2.3. Aggregation approach
PRP or washed platelets (2.5  108 platelets/mL in HEPES-Tyrodes) were used for aggregation
studies. Aggregations were performed with 300mL aliquots of PRP or washed platelets that were
warmed at 37 C for 4 min without stirring and for 1 min with constant stirring at 1200 rpm in a
Chrono-log aggregometer, before stimulation with the corresponding agonists for 6 min.
The following agonists were used: Crosslinked collagen-related peptide (CRP), with the sequence
Gly-Cys-Hyp-(Gly-Pro-Hyp)10-Gly-Cys-Hyp-Gly-NH2, was provided by Dr. Richard W. Farndale, from
the University of Cambridge (UK). Collagen Reagent HORM® Suspension (KRH) was purchased from
Takeda Austria GmbH (Austria). Thrombin and ADP were purchased from Sigma (Sigma-Aldrich, St.
Louis, MO) and arachidonic acid from Cayman Chemical (Michigan, USA). Rhodocytin was provided by
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Frankfurt University Hospital, Frankfurt am Main, Germany.
Regarding the activating condition, PRP stimulations were done with collagen-related peptide
(CRP)-XL (0.1, 0.15 and 0.2 mg/mL), Horm collagen (0.5, 0.75 and 1 mg/mL), rhodocytin (25 and 50nM),
ADP (2 and 3 mM) and arachidonic acid (0.3 and 0.5mM). On the other hand, washed platelets were
activated with collagen-related peptide (CRP)-XL (0.4, 0.5 and 1 mg/mL), Horm collagen (1, 2 and 3 mg/
mL), rhodocytin (25, 50 and 100nM) and thrombin (0.5 and 0.75 U/mL).
2.4. 2D-DIGE approach
For proteomic analysis, proteins were precipitated in 20% trichloroacetic acid in acetone, as pre-
viously described [2]. Protein pellets were resuspended in 60 mL DIGE buffer (65 mM CHAPS, 5 M urea,
2 M thiourea, 0.15 M NDSB-256, 30 mM Tris, 1 mM sodium vanadate, 0.1 mM sodium fluoride, and 1
mM benzamidine). Protein quantitation was done with Coomassie Plus protein reagent (Thermo
Scientific).
Six gels (technical replicates) were run in the experiment with a total of 150 mg of mixed labeled
protein per gel. These protein mixtures contained 50 mg of protein from each sample (10 obese pooled
and 10 lean pooled matched-controls) randomly labeled with 400 pmol minimal CyDye DIGE fluors
(Cy3 and Cy5), and 50 mg of a pool of both conditions (25 mg from obese patients and 25 mg from lean
controls) labeled with 400 pmol Cy2 (internal standard). Labelling was performed for 30 min on ice in
the dark. The reaction was stopped with 1 ml of 10 mM lysine acting for 10 min on ice in the dark. After
labelling step, the three samples were pooled and an equal volume of 2 sample buffer was added (65
mM CHAPS, 2 M thiourea, 5 M urea, 0.15 M NDSB-256, 130 mM DTT, 4 mM tributylphosphine, 1 mM
sodium vanadate, 0.1 mM sodium fluoride, and 1 mM benzamidine).
After mixing, the tubewas left for 10 min on ice in the dark. For reswelling, samples were diluted up
to a total of 500 ml of 2D Sample buffer (5 M urea, 2 M thiourea, 2 mM tributylphosphine, 65 mM DTT,
65 mM CHAPS, 0.15 M NDSB-256, 1 mM sodium vanadate, 0.1 mM sodium fluoride, and 1 mM ben-
zamidine, final concentration), and ampholytes (Servalyt 4e7) were added to a final concentration of
1.6% (v/v). IPG strips were rehydrated with the samples for 16 h in the dark. Isoelectric focusing (IEF)
was run on 24 cm, pH 4e7 IPG strips (GE Healthcare) powered by a Multiphor II (GE Healthcare) for
64.9 kVh at 17 C.
Following the first dimension, IPG strips were immediately equilibrated for 15 min in reduction
buffer (6 M urea, 50 mM tris pH 8.8, 30% glycerol, 2% w/v SDS, 65 mM DTT and traces of bromophenol
blue) and then for 15 min in alkylation buffer (6 M urea, 50 mM tris pH 8.8, 30% glycerol, 2% w/v SDS,
135 mM iodoacetamide and traces of bromophenol blue) with gentle agitation; all steps in the dark.
IPG strips were washed out with ultrapure water and placed on top of the second dimension gels,
embedded with 0.5% melted agarose.
Proteinswere separated in the second dimension by SDS-polyacrylamide gel electrophoresis (PAGE)
on 11% polyacrylamide gels at run conditions of 10 C, 20 mA per gel for 1 h, followed by 40 mA per gel
for 4 h by using an Ettan Dalt 6 system (GE Healthcare). Following electrophoresis gels were scanned
directly in a Typhoon FLA 7000 scanner (GE Healthcare). After imaging, gels were fixed in 10%
methanol/7% acetic acid for 1 hour, and stained overnight with Sypro Ruby fluorescent dye for spot
picking.
2.5. Differential image analysis
Scanned images were processed with Progenesis SameSpots (Version 4.5) from Nonlinear Dy-
namics. Manual and automatic alignment was used to align the images. SameSpots detects the spots
simultaneously across all images generating a master gel list containing all the features. Internal
calibration of the 2D-DIGE gel images with regard to pI and molecular weight was carried out with
SameSpots built-in tools. All gels were compared with each other, and fold values as well as P values of
all spots were calculated by SamesSpots Version 4.5 software using 1-way ANOVA analysis. Differential
expression of a protein present in the gels was considered significant when the fold changewas at least
1.2 and the P value was <0.05.
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Differential regulated spots were excisedmanually from the gels and in-gel digested with trypsin as
previously indicated [4]. Most of the identifications were by LCeMS/MS on an EASY-nLC (Proxeon,
Bruker Daltonics) and a Bruker Amazon ETD ion trap. Remaining identifications were by MALDI-TOF(/
TOF), in a 4800 Plus MALDI-TOF/TOF analyzer (Applied Biosystems).
For LC-MS/MS analysis, digested peptide mixtures were dissolved in 0.1% formic acid and were
separated in an EASY-nLC (Proxeon, Bruker Daltonik GmbH) with a reverse phase nanocolumn (Easy
column SC200) from Proxeon (see below for more details).Table: LC parameters for separation of tryptic peptides
LC settings
LC system Easy-nLC PROXEON
Trap column Easy-column SC001 L 2 cm, ID 100 mm, 5 mm, 120 A, C18-A1 from Proxeon
Analytical column Easy column SC200C18 3mm 120A 360 mm OD/75mm ID, L ¼ 10cm) from Proxeon
Flow rate 300 nl/min
Eluents A:0.1% FA in water B:0.1%FA in ACN
Gradient 5% (t ¼ 0 min), 35% (t ¼ 32 min), 50% (t ¼ 37 min), 100% (t ¼ 38min)Ionized peptides were analyzed in a CID-ETD ion trap mass spectrometer (Bruker Daltonics),
equippedwith a Nanosprayer ionization source that was used for data-dependentMS/MS experiments.
Spectra were acquired in Enhanced Resolution mode. Further acquisition parameters are listed in




Scan mode Enhanced resolution mode (8100 m/z s1)
Scan range 50e3000 Da
Spectra averages 5 (Rolling averaging: 1)
MS/MS settings:
Scan mode UltraScan
Scan range 100-3000 m/z
No. of precursor ions 3 (active exclusion after 1 spectrum, release after 0.2 min;
reconsider precursor, if current intensity/previous intensity >1%
Isolation width 4 m/z
Spectral averages 2
Fragmentation amplitude (CID) 30e300%
Fragmentation time (ETD) 100 msAutomated analysis of mass data was achieved by Data Analysis 4.0 and BioTools 3.2 from Bruker
Daltonik GmbH. Database search was performed with the Mascot v2.3.0 search tool (Matrix Science,
London, UK) screening SwissProt (SwissProt_2016_09.fasta). Searches were restricted to human tax-
onomy allowing carbamidomethyl cysteine as a fixed modification and oxidized methionine as po-
tential variable modification. Both the precursor mass tolerance and the MS/MS tolerance were set at
0.3 and 0.4 Da, respectively, allowing 1 missed tryptic cleavage site. All spectra and database results
were manually inspected in detail using the above software, especially in the case of identifications
based on one peptide hit. For the latter, positive identification by MS was only accepted when more
than 50% y-ions (CID fragmentation) or z-ions (ETD fragmentation) were obtained for a peptide
comprising at least eight amino acids long and no missed tryptic cleavage site. Positive hits corre-
sponded to Mascot scores >40 plus the fulfillment of the above criteria.
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of peptide andmatrix solution (3 mg alpha-cyano-4-hydroxycinnamic acid (a-CHCA) dissolved in 1 mL
of 50% acetonitrile in 0.1% trifluoroacetic acid) were deposited using the thin layer method, onto a 384
Opti-TOF 123  81 mm MALDI plate (Applied Biosystems) and allowed to dry at room temperature.
Mass spectrometric data were obtained in an automated analysis loop using a 4800 MALDI-TOF/TOF
analyzer (Applied Biosystems). Spectra were acquired in the reflector positive-ion mode with a
Nd:YAG, 355nmwavelength laser, at 200 Hz laser frequency, and 1000 to 2000 individual spectra were
averaged. The experiments were acquired uniform with fixed laser intensity. All MSMS spectra were
performed by selecting the precursors with a relative resolution of 300 (FWHM) and metastable
suppression.
Automated analysis of mass data was achieved by using the 4000 Series Explorer Software V3.5
(Applied Biosystems). Internal calibration ofMALDI-TOFmass spectrawas performed using two trypsin
autolysis ions withm/z¼ 842.510 andm/z¼ 2211.105. For MALDI-MS/MS, calibrations were performed
with fragment ion spectra obtained for Angiotensin II (peptide mix, calibration standard, Bruker). MS
and MS/MS spectra data were combined through the Protein Pilot Explorer Software v4.5. Database
search was performed with the Mascot v2.1 search tool (Matrix Science, London, UK) screening
SwissProt (release version 2016e05; February 551193 entries). Searches were restricted to Human
taxonomy allowing carbamidomethyl cysteine as a fixed modification and oxidized methionine as
potential variablemodification. Both the precursormass tolerance and theMS/MS tolerancewere set at
100 ppm and 0.3 Da, respectively, allowing 1 missed tryptic cleavage site. MALDI-MS(/MS) spectra and
database search results were manually inspected in detail using the previous software. For combined
MS and MS/MS data, identifications were accepted when Confidence Interval (C.I.%) of Protein Pilot
software was 95% or higher. Since Protein Scores and Ion Scores from different searches cannot be
directly compared, Protein Pilot software calculates this C.I.% in order to combine results from MS and
MS/MS database searches. This coefficient value means that the probability that the observed match is
a random event is lower than 5%. For PMF spectra, identifications were also accepted when (C.I.%) of
Protein Pilot software was 99% or higher.
2.7. Western blotting
Western blotting was performed for validation purpose. 1D-western blotting was carried out to
validate individual samples (biological replicates). 11% SDS-PAGE gels were used, loading 10 mg of
protein per lane. For 2D-western blotting validations, IPG strips 4e7, 7 cm (GE Healthcare), were used.
Thirty micrograms of protein were loaded per strip; obese and lean-matched samples (pools of 5 in-
dividuals per each condition) were analyzed in parallel. Samples were analyzed in triplicate. IEF (first
dimension) was for 11Kvh; second dimension was also on 11% SDS-PAGE gels.
Following electrophoresis, proteins were transferred onto polyvinylidene difluoride (PVDF) mem-
branes. Membranes were blocked in 5% BSA in TBS-T (20 mM Tris-HCl, (pH 7.6), 150 mM NaCl and 0.1%
Tween 20) overnight at 4 C and incubated for 90min at room temperature with the following primary
antibodies: rabbit anti-phospho-SRC (Tyr418) (Invitrogen), dilution 1:1000; rabbit anti-SRC pan
(Invitrogen), dilution 1:1000; mouse anti-FIB (sc-69775, Santa Cruz), dilution 1:1000; mouse anti-
PLCg2 (sc-5283, Santa Cruz), dilution 1:1000; rabbit anti-GAPDH (SIGMA), dilution 1:5000; and anti-
G6f (1:1000), produced by CovalAB UK (Cambridge, UK). Following washes in TBS-T, membranes were
exposed to horseradish peroxidaseelabeled goat anti-rabbit, or goat anti-mouse antibodies (dilution
1:5000) (Pierce, Rockford, IL), and processed using an enhanced-chemiluminiscence system (ECL,
Pierce, Rockford, USA).
2.8. Immunoprecipitation
Basal and activated platelets (8  108platelets/mL, 500 mL per immunoprecipitation; activations
with CRP-XL 1 mg/mL, 90sec) were lysed with 500 mL NP40-based lysis buffer, (0.3 M Sodium Chloride,
20mM Tris, 2mM EGTA, 2mM EDTA, 2% (v/v) NP-40, pH 7.5). Activations were under non-aggregating
conditions in the presence of integrilin (9 mM). For phosphotyrosine (p-Tyr) immunoprecipitations, 5
mg of agarose-conjugated 4G10 monoclonal anti-phosphotyrosine antibody (EMD Millipore
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rotated overnight at 4 C. Before the addition of the antibodies, samples were precleared with 25 mL of
Protein A-Sepharose (50% w/v in TBS-T (20mM Tris-HCl (pH 7.6), 137mMNaCl, and 0.1% v/v Tween 20))
at 4 C for 60 minutes with end-over-end mixing. After immunoprecipitations, proteins were eluted
from the beads in 2X Laemmli sample buffer (4% w/v SDS, 10% v/v 2-mercaptoethanol, 20% v/v glycerol,
50 mM Tris, pH 6.8) and resolved on 4e12% NuPAGE Bis-Tris gradient gels (Invitrogen, Carlsbad, CA,
USA) for western blotting.
2.9. Flow cytometry
We analyzed the expression of GPVI in whole blood and P-selectin in washed platelets. To measure
GPVI dimer, GPVI total and P-selectin, 10 ml of platelet solution, either 5-fold diluted whole blood or
washed platelets (5107 cells/mL), wasmixedwith 10 ml of 204e11 Fab (GPVI-dimer-specific; 5 mg/mL,
final), 1G5 (pan GPVI; 10 mg/mL, final) (Biocytex, France) and CD62 (10 mg/mL, final) (ABCAM, UK) and
incubated for 10 min. For all of them, ALEXA 488 anti-mouse F(ab)2 antibody (50 mg/ml, final) (Jackson
ImmunoResearch) was added as the secondary antibody and incubated for 10 min. In individual
Eppendorf tubes each reaction mixture was diluted with 0.200 ml of diluent (Beckman Coulter, USA),
and then antibody binding was measured by an Accuri C6 flow cytometer (BD Biosciences). Platelet
binding to appropriate controls, mouse Fab (Jackson ImmunoResearch) when the primary antibody
was 204e11 Fab, IgG2Awhen it was 1G5 and IgG1when it was CD62, was determined. The test was run
in triplicate and the average of mean fluorescence intensity was measured.
2.10. Systems biology
Ingenuity Pathways Analysis software (IPA, Ingenuity Systems, www.ingenuity.com) was used to
investigate possible interactions among all the identified proteins. Interactive pathways were
generated to observe potential direct and indirect relations among the differentially regulated
proteins. STRING v10 software [5] was also used to predicted protein-protein interactions and to
know the biological process, molecular functions and cellular components where the differential
proteins were involved.
2.11. Statistical analysis
Categorical variables from obese patients and lean matched-controls are expressed as percentages
andwere compared using the Fisher exact test. Continuous variables are expressed as themedian ± SD,
and were compared by the Mann-Whitney test. Correlations analyses were done using the Spearman's
test.
As indicated above, the differential proteomic analysis was done analyzing all the spots between
obese patients and lean matched-controls; for a given spot, the probability value was calculated using
the quantified and normalized volumes for the matched spot. All probability values were calculated
using 1-way ANOVA analysis and values of p < 0.05 were considered statistically significant.
Following 1D-western blotting validation studies, densitometry of the bands were performed using
ImageJ (National Institute of Health, Bethesda, MD, USA) version 1.47, and statistical analysis by
ManneWhitney test comparing groups. Graphs were done with GraphPad Prism 5 (GraphPad Soft-
ware, Inc. San Diego California, USA). All analyses were performed using IBM SPSS Statistics 20 software
for Windows (IBM, Armonk, NY, USA).
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